Vernalis (VER)

 

VER Share PerformanceMore

52 week high65.000 01/03/16
52 week low25.000 24/02/17
52 week change -29.250 (-53.18%)
4 week volume11,610,571 30/01/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Unaudited interim results for 6 months to 31/12/16

RNS Number: 3708X Vernalis PLC 21 February 2017 21 February 2017 Vernalis plc Unaudited Interim Results for the six months ended 31 December 2016 Tuzistra XR prescriptions growing steadily as 2016/2017 US cough cold season progresses Two further NDAs from cough cold franchise accepted for review by FDA with potential approvals later this year Vernalis...

Broker Forecast - Stifel issues a broker note on Vernalis PLC

Stifel today reaffirms its buy investment rating on Vernalis PLC (LON:VER) and set its price target at 104p.

Achievement of a $3m milestone payment from Corvus

RNS Number: 7745W Vernalis PLC 14 February 2017 14 February 2017 LSE: VER Vernalis achieves a $3 million milestone payment from Corvus Pharmaceuticals Inc Vernalis plc is pleased to announce the achievement of a clinical milestone from its collaboration with Corvus Pharmaceuticals Inc ("Corvus") triggering a payment of $3 million to Vernalis. In Februa...

Vernalis schedules interims

Vernalis will announce its unaudited interim results for the six months ended 31 December on 21 February. At 1:03pm: (LO...

Notice of Results for Six Months Ended 31/12/2016

RNS Number: 4717V Vernalis PLC 30 January 2017 30 January 2017 Vernalis plc ("Vernalis" or the "Company") Notice of Results for the Six Months Ended 31 December 2016 Vernalis plc (LSE: VER) announces that its unaudited interim results for the six months ended 31 December 2016 will be released on Tuesday, 21 February 2017. The results announcement will ...

Versarien Plc to present at the Shares Spotlight Evening in London on 9 February 2017

Neill Ricketts, CEO of Versarien (VRS) (LSE:VRS) will give a presentation at the Shares Spotlight Evening on 9 February 2...

Vernalis says FDA accepts CCP-08 NDA for full review

Vernalis and Tris Pharma Inc announce that the US Food and Drug Administration (FDA) has accepted the CCP-08 New ...

FDA accepts CCP-08 NDA for full review

RNS Number: 4179S Vernalis PLC 21 December 2016 21 December 2016 LSE: VER FDA accepts CCP-08 NDA for full review PDUFA date of 4 August 2017 Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug Administration ("FDA") has accepted the CCP-08 New Drug Application ("NDA") for full review. This triggers a m...

Fundamental DataMore

EPS-3.2
Dividend yield0 %

Equity Research (VER)

edison investment research
Vernalis plc
05/01/2017
FDA acceptance of the CCP-08 NDA (setting a 4 August 2017 PDUFA date) advances Vernalis towards its goal of building a speciality US franchise of extended release (ER) prescription-only (Rx) cough...
edison investment research
Vernalis plc
21/10/2016
Vernalis marked its transition into a commercial-stage speciality pharma company with the September 2015 US launch of Tuzistra XR, the first product from its extended release (ER) prescription only (...
edison investment research
Vernalis plc
25/05/2016
The issue of 80m new shares at 50p/share has raised £40m (gross), which enables Vernalis to focus on executing its operational plan and removes uncertainty over whether it is sufficiently funded...

Latest discussion posts More

  • Now Woody's Buying

    Just me and him then, anyone else? M
    26-Jul-2016
    sound money
  • More Director Buying.

    Wow these guys really believe this is a winner. Glad I bought in last week. M
    9-Jun-2016
    sound money
  • Edison Note - Research Tree

    Read Edison's note on VERNALIS, out this morning, by visiting https://www.research-tree.com/company/GB00B3Y5L754 "Vernalis intends to raise #40m (gross) through the issue of ...
    28-Apr-2016
    FoxRed

Users' HoldingsMore

Users who hold Vernalis also hold..
LLOYDS GRP.34%
VODAFONE GRP.22%
BT GROUP20%
BP18%
ROYAL BANK SCOT18%

Codes & Symbols

ISINGB00B3Y5L754
SymbolsVER, LSE:VER, VER.L, VER:LN, LON:VER, XLON:VER